Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
It has been demonstrated that immune checkpoint blockade has efficacy similar to chemotherapy in the neoadjuvant setting. Biomarkers such as PD-L1 expression levels can be used to rationally design clinical trials aimed at personalizing systemic therapy for patients with muscle-invasive bladder cancer.